Suzhou's Adagene Raises $8 Million For Antibody Discovery
Adagene Inc., a Suzhou antibody discovery and engineering company, closed an $8 million Series A round of financing with participation by two Fidelity funds -- Fidelity Biosciences and Fidelity Asia Growth -- along with the WuXi Venture Fund, the investment arm of WuXi PharmaTech (NYSE: WX) (see story). Adagene partners with other pharmas to develop antibodies for the partners' needs and is also building its own portfolio of products, which it will out-license later in their development.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.